HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of vanadium on insulin sensitivity and appetite.

Abstract
Vanadium, a potent nonselective inhibitor of protein tyrosine phosphatases, has been shown to mimic many of the metabolic actions of insulin both in vivo and in vitro. The mechanism(s) of the effect of vanadium on the decrease in appetite and body weight in Zucker fa/fa rats, an insulin-resistant model, is still unclear. Because insulin may inhibit hypothalamic neuropeptide Y (NPY), which is known to be related to appetite, and increase leptin secretion in adipose tissue, we studied the possibility that the changes in appetite produced by vanadium may be linked to altered NPY levels in the hypothalamus. We also examined effects of vanadium on leptin. Zucker lean and fatty rats were chronically treated with bis(maltolato)oxovanadium(IV) (BMOV), an organic vanadium compound, in the drinking water. Plasma and adipose tissue leptin levels were measured by radioimmunoassay and immunoblotting, respectively. Hypothalamic NPY mRNA and peptide levels were measured using in situ hybridization and immunocytochemistry, respectively. BMOV treatment significantly reduced food intake, body fat, body weight, plasma insulin levels, and glucose levels in fatty Zucker rats. Fifteen minutes after insulin injection (5 U/kg, intravenous [IV]), circulating leptin levels (+100%) and adipose leptin levels (+60%) were elevated in BMOV-treated fatty rats, although these effects were not observed in untreated fatty rats. NPY mRNA levels in the arcuate nucleus (ARC) (-29%), NPY peptide levels in ARC (-31%), as well as in the paraventricular nucleus (PVN) (-37%) were decreased with BMOV treatment in these fatty rats. These data indicate that BMOV may increase insulin sensitivity in adipose tissue and decrease appetite and body fat by decreasing NPY levels in the hypothalamus. BMOV-induced reduction in appetite and weight gain along with normalized insulin levels in models of obesity, suggest its possible use as a therapeutic agent in obesity.
AuthorsJ Wang, V G Yuen, J H McNeill
JournalMetabolism: clinical and experimental (Metabolism) Vol. 50 Issue 6 Pg. 667-73 (Jun 2001) ISSN: 0026-0495 [Print] United States
PMID11398143 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2001 by W.B. Saunders Company
Chemical References
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Leptin
  • Neuropeptide Y
  • Pyrones
  • RNA, Messenger
  • Vanadium
  • bis(maltolato)oxovanadium(IV)
  • Vanadates
Topics
  • Adipose Tissue (drug effects, metabolism)
  • Animals
  • Appetite (drug effects)
  • Arcuate Nucleus of Hypothalamus (drug effects, metabolism)
  • Blood Glucose (analysis)
  • Cell Nucleus (metabolism)
  • Disease Models, Animal
  • Hypoglycemic Agents (pharmacology)
  • Hypothalamus (drug effects, metabolism, physiology)
  • Immunohistochemistry
  • In Situ Hybridization
  • Insulin (blood, pharmacology)
  • Leptin (analysis, blood)
  • Male
  • Neuropeptide Y (analysis, blood)
  • Obesity (blood, metabolism)
  • Pyrones (pharmacology)
  • RNA, Messenger (analysis)
  • Rats
  • Rats, Zucker
  • Vanadates (pharmacology)
  • Vanadium (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: